Skip to main content
. 2023 Jan 21;15(3):667. doi: 10.3390/cancers15030667

Figure 4.

Figure 4

Increased proportion of Tregs TNFR2+ and IL-6 in the pre-treatment peripheral blood of patients with advanced HGSOC (n = 33) compared to benign (n = 12) and normal ovaries (n = 21). (A) Flow cytometry plot of proportion of Tregs, CD25hiFOXP3+. (B) Flow cytometry plot of frequency (%) and expression (MFI, median fluorescence intensity) of TNFR2+ Tregs in advanced HGSOC patients (n = 33) compared to those with benign ovarian masses (n = 12) and normal ovaries. (C) The proportion of Tregs TNFR2+ (in colored font and top right-hand column with black arrow) and level of expression (MFI) of TNFR2-expressing Tregs between three study groups. (D) The level of IL-6 (pg/mL) in the serum between three study groups. One-way ANOVA and Dunn’s multiple comparison test (post hoc); * p < 0.05, ** p = 0.001–0.01, *** p = 0.0001–0.001, **** p < 0.0001 (error bars—SEM).